Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nicholls

Showing results (1331-1340 of 1,396) with videos related to

Pageof 140
Sort By:
JAMA|March 28, 2026
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV TrialNicholas A Marston, Erin A Bohula, Ajay K Bhatia, et al.
American Heart Journal|May 17, 2026
Cardiovascular Regulatory Science: Accelerating the Path from Bench to BedsideSerge Korjian, C Michael Gibson, Jonathan Seltzer, et al.
The Lancet Regional Health. Western Pacific|June 19, 2026
Systematic review of cardiovascular care delivery across health systems in the Asia-Pacific: a regional roadmap for strengthening cardiovascular careNicholas Ws Chew, Gwyneth Kong, F Aaysha Cader, et al.
Eneuro|January 13, 2023
Measuring Nonapoptotic Caspase Activity with a Transgenic Reporter in MiceP J Nicholls, Thomas F Pack, Nikhil M Urs, et al.
Circulation. Heart Failure|January 11, 2011
A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trialDavid A Baran, Mark J Zucker, Luis H Arroyo, et al.
Atherosclerosis Plus|April 15, 2024
Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trialYu Kataoka, Satoshi Kitahara, Sayaka Funabashi, et al.
JAMA|November 15, 2020
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical TrialStephen J Nicholls, A Michael Lincoff, Michelle Garcia, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 31, 2020
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effectsJian-Jun Li, Hui-Hui Liu, Na-Qiong Wu, et al.
European Heart Journal|December 22, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWilliam T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.
Nature Medicine|February 27, 2026
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Pageof 140

Showing results (1331-1340 of 1,396) with videos related to

Sort By:
Pageof 140
JAMA|March 28, 2026
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV TrialNicholas A Marston, Erin A Bohula, Ajay K Bhatia, et al.
American Heart Journal|May 17, 2026
Cardiovascular Regulatory Science: Accelerating the Path from Bench to BedsideSerge Korjian, C Michael Gibson, Jonathan Seltzer, et al.
The Lancet Regional Health. Western Pacific|June 19, 2026
Systematic review of cardiovascular care delivery across health systems in the Asia-Pacific: a regional roadmap for strengthening cardiovascular careNicholas Ws Chew, Gwyneth Kong, F Aaysha Cader, et al.
Eneuro|January 13, 2023
Measuring Nonapoptotic Caspase Activity with a Transgenic Reporter in MiceP J Nicholls, Thomas F Pack, Nikhil M Urs, et al.
Circulation. Heart Failure|January 11, 2011
A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trialDavid A Baran, Mark J Zucker, Luis H Arroyo, et al.
Atherosclerosis Plus|April 15, 2024
Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trialYu Kataoka, Satoshi Kitahara, Sayaka Funabashi, et al.
JAMA|November 15, 2020
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical TrialStephen J Nicholls, A Michael Lincoff, Michelle Garcia, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 31, 2020
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effectsJian-Jun Li, Hui-Hui Liu, Na-Qiong Wu, et al.
European Heart Journal|December 22, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWilliam T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.
Nature Medicine|February 27, 2026
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Pageof 140